Talk about a study in contrasts.

On Tuesday, the Food and Drug Administration issued a warning about contrast agents used in MRI scans, over concerns they contain a potentially toxic metal that can be left in the brain tissue. But regulators elsewhere have been far tougher on the issue: Last week, the U.K. National Health Service suspended two agents over the same concerns. The European Medicines Agency, meanwhile, has suspended use of three agents. Last month, Japan also restricted usage of some agents.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • A study ‘in contrasts,’ indeed! There are those who see it as clearly ‘black and white’ rather than White Oaks ‘many shades of gray.’

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy